Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Kate Newbold, Shreerang Bhide, Alan Melcher, Amy Trinh, KH Wong, Pablo Nenclares, Lucinda Gunn, Heba Soliman, Mateo Bover, Kevin J. Harrington, Christopher M. Nutting, Isla Leslie, Derfel Ap Dafydd
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundPrevious studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with
Autor:
Robert H.I. Andtbacka, Frances A. Collichio, Gerald Downey, Kevin J. Harrington, Howard L. Kaufman, Mark R. Middleton, Katarina Ӧhrling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB
Autor:
Mansour T. A. Sharabiani, Paul Carter, S.A. Bhide, Kevin J. Harrington, R. Shaikh, Isaac Garcia-Murillas, D.M. Allin, Katie L. Newbold, Khin Thway, D. Kim, D. Gonzales-de-Castro, Ben O'Leary, Mike Hubank
Publikováno v:
European Journal of Cancer. 103:165-175
Background Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in other solid tumours. This is a
Autor:
Syed Haider, Robert S. Coffin, Eva Crespo-Rodriguez, Khin Thway, Richard Buus, Alan Melcher, Richard G. Vile, Harriet Whittock, Emmanuel C Patin, Galabina Bozhanova, Kate Newbold, Dae Kim, Katharina F. Bergerhoff, Malin Pedersen, Gareth Muirhead, Martin McLaughlin, Shane Foo, Kevin J. Harrington
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mut
Autor:
Sara Reis, Intan Hamid, Sophie McGrath, Susannah Stanway, Alicia Okines, Jaishree Bhosle, Vasileios Angelis, Marco Gerlinger, Heba Soliman, Zayd Tippu, Firza Gronthoud, Robin L. Jones, Emma Cottier, Charlotte Fribbens, Jillian Noble, David Watkins, Spyridon Gennatas, Kroopa Joshi, Pablo Nenclares, Kevin J. Harrington
Publikováno v:
European Journal of Cancer
Background In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted.
Autor:
Kevin J. Harrington, Pablo Nenclares, Sheerang A. Bhide, Alan Melcher, Kate Newbold, Christopher M. Nutting, Pierre Pialat, Helena Sandoval-Insausti, Lucinda Gunn
Publikováno v:
European journal of cancer (Oxford, England : 1990). 131
Background Pre-clinical evidence suggests reduced efficacy of anticancer treatment in patients exposed to broad-spectrum antibiotics. It is hypothesised that this phenomenon may be explained by the effects of antibiotics on the composition of the mic
Autor:
Andrew J. Hayes, Aadil A. Khan, Kevin J. Harrington, Henry G. Smith, Tim Pencavel, Michelle J. Wilkinson, Joan Kyula-Currie, Gráinne McEntee, Victoria Roulstone, David Mansfield
Publikováno v:
Oncotarget
Advanced extremity melanoma and sarcoma present a significant therapeutic challenge, requiring multimodality therapy to treat or even palliate disease. These aggressive tumours are relatively chemo-resistant, therefore new treatment approaches are ur
Autor:
Linta Kuncheria, Robert S. Coffin, David Mansfield, Kevin J. Harrington, Howard L. Kaufman, Suzanne Thomas, Henry G. Smith, Praveen K. Bommareddy, Joan N. Kyula, Victoria Roulstone
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Background Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development as an oncolytic immunotherapy
Autor:
Éva Remenár, Martin Forster, Judit Kocsis, Magnus T. Dillon, Jonathan Greenberg, Frederic Rolland, Gábor Pajkos, Kevin J. Harrington
Publikováno v:
European journal of cancer (Oxford, England : 1990). 123
Background The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCC
Autor:
Nicola E. Annels, Richard G. Vile, Mehreen Arif, M. Denyer, Darren R. Shafren, Izhar Bagwan, Carmen Ballesteros-Merino, Bernard A. Fox, Bronwyn Davies, Guy Simpson, Hardev Pandha, Gough G. Au, David Mansfield, Kevin J. Harrington, Mark Grose, Sarbjinder S Sandhu, Hugh Mostafid, Alan Melcher
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(19)
Purpose: The CANON [CAVATAK in NON–muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods: Fifteen patients enro